ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Heart and Lung Transplants From HCV-Infected Donors to Uninfected Recipients

Sunday, April 28, 2019

Submitted by

Arie Blitz

Source

Source Name: The New England Journal of Medicine

Source URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1812406

Author(s)

Ann E. Woolley, Steve K. Singh, Hilary J. Goldberg, Hari R. Mallidi, Michael M. Givertz, Mandeep R. Mehra, Antonio Coppolino, Amanda E. Kusztos, Megan E. Johnson, Kaiwen Chen, Esther A. Haddad, John Fanikos, David P. Harrington, Phillip C. Camp, Lindsey R. Baden, for the DONATE HCV Trial Team

The authors of this single-center open-label pilot trial evaluated the intermediate-term outcomes of patients undergoing either heart (n=8) or lung (n=36) transplantation from donors that had evidence of active hepatitis C virus (HCV) infection. All patients underwent treatment of HCV antiviral treatment for 4 weeks after transplantation. The primary outcome measured was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival 6 months after transplantation. Of the initial 35 patients who had completed 6 months of follow-up, all patients met the primary outcome. Thus, at intermediate term follow-up, HCV infection was prevented in 100% of patients.